Table 3.
Peak Hb A Modifications (%) and AUC24h (%·h) of Test Compounds Incubated at 2 mM Concentration with Blood from Healthy Donorsa
| compound | peak Hb 5 A modification (%) | AUC24h (%·h) |
|---|---|---|
| 5-HMF | 26.1 | 272.2 |
| Ester Derivatives | ||
| VZHE004 | 23.8 | 256.4 |
| VZHE006 | 25.1 | 227.6 |
| VZHE007 | 21.0 | 203.4 |
| VZHE014 | 12.7 | 116.1 |
| Alkyl Ether Derivatives | ||
| VZHE005 | 21.0 | 212.5 |
| VZHE011 | 27.9 | 271.5 |
| VZHE013 | 6.3 | 36.7 |
| VZHE015 | 25.4 | 230.7 |
| VZHE016 | 15.8 | 153.0 |
| Aryl Ether Derivatives | ||
| 5-NMFC | 24.7 | 350.9 |
| 5-PMFC | 27.9 | 383.7 |
a
All studies were conducted with AA cells suspensions (30% hematocrit) incubated with 2 mM of each test compound, and values are reported from a single experiment. Hb A modification values were obtained from HPLC analyses of hemolysates at the end of the assay. Peak adduct concentration was obtained by visual inspection and area under the curve, AUC(0–24) was obtained by the linear trapezoidal rule across the entire 24-h measurement period.